BREAKING NEWS—UK approves BioNTech's COVID-19 vaccine

BioNTech and Pfizer announced today that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a temporary authorization for emergency use for their COVID-19 vaccine BNT162b2.

This constitutes the first Emergency Use Authorization for the vaccine anywhere in the world.

The MHRA’s decision is based on a rolling submission, including data from the Phase III clinical study, which demonstrated a vaccine efficacy rate of 95%.

Pfizer and BioNTech have an agreement with the UK to supply 40 million doses of the BNT162b2; the delivery will occur throughout 2020 and 2021 in stages to ensure an equitable allocation of vaccines across the geographies with executed contracts.

Look out for more details on this on The Pharma Letter website.